1.67
+0.54(+47.79%)
Currency In USD
| Previous Close | 1.13 |
| Open | 1.78 |
| Day High | 1.8 |
| Day Low | 1.55 |
| 52-Week High | 124.8 |
| 52-Week Low | 0.85 |
| Volume | 48.02M |
| Average Volume | 266,488 |
| Market Cap | 4.64M |
| PE | -0.03 |
| EPS | -59.81 |
| Moving Average 50 Days | 1.2 |
| Moving Average 200 Days | 19.66 |
| Change | 0.51 |
If you invested $1000 in Eyenovia, Inc. (EYEN) since IPO date, it would be worth $2.01 as of May 20, 2025 at a share price of $1.595. Whereas If you bought $1000 worth of Eyenovia, Inc. (EYEN) shares 5 years ago, it would be worth $6.19 as of May 20, 2025 at a share price of $1.595.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
GlobeNewswire Inc.
Apr 10, 2025 11:00 AM GMT
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and com
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq
GlobeNewswire Inc.
Mar 20, 2025 11:00 AM GMT
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenov
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
GlobeNewswire Inc.
Feb 26, 2025 12:00 PM GMT
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informe